Skip to main content
Gilead10-Q: Goodwill impairment

Gilead records $1.75 billion IPR&D impairment following discontinuation of Phase 3 EVOKE-03 study

Source: Autobound Signal API · 68 signals tracked for Gilead · updated

Get Gilead's live signals in Claude or ChatGPT, or by API

AskWhat changed at Gilead this week? Use Autobound signals for gilead.com.

What happened

Gilead recognized an impairment charge of $1.75 billion for the NSCLC IPR&D intangible asset after discontinuing its Phase 3 EVOKE-03 study evaluating Trodelvy. This represents a significant pipeline setback that may prompt management to evaluate external R&D solutions or alternative oncology assets.

Source

SEC EDGAROct 29, 2026

Quarterly report (Form 10-Q)

Gilead 10-Q for Quarter ended Sep 30, 2026

Filing excerpt

In consideration of this decision, and in connection with the preparation of the financial statements for the second quarter of 2026, we determined that no future cash flows were expected to be generated in relation to the NSCLC IPR&D intangible asset, and therefore, no value was attributed to the asset. As a result, we recognized an impairment charge of the remaining balance of $1.75 billion in In-process research and development impairments on our Condensed Consolidated Statements of Operations for the nine months ended September 30, 2026.

sec.gov/Archives/edgar/data/882095/000088209526000039/gild-20260930.htmRead the full source

Other signals in this filing (5)

Extracted by Autobound

From the Signal API record
Signal
10-Q: Goodwill impairment

What this signalsFilings often name leadership changes, deals and spending plans.

Period
Quarter ended Sep 30, 2026
Fiscal year end
09/30
Filed
Oct 29, 2026

More 10-Q signals at other companies

The full record

From the Signal API record

Numbers

Dollar figure
$1.8B (impairment charge of NSCLC IPR&D intangible asset)

Details

CIK
882095
Accession number
0000882095-26-000039
Timeframe
Current year
Quarter
Q3
Filing year
2026
Period end date
Sep 30, 2026
Why it matters
Strategic review underway
Signal category
Financial

Extraction

Confidence
High
Relevance
80%
Sentiment
Negative
Detected
Nov 3, 2026
signal_type
sec-10q
signal_subtype
goodwillImpairment

Use this data

Get every 10-Q signal for Gilead and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Gilead this week?”

  2. Send it to your own tools

    The Signal API returns 10-Q signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full sec-10q record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/45049ea8-d1aa-431d-9ac1-9c817cabf3fb returns this record as JSON. POST /v1/companies/enrich returns every signal for gilead.com.

{
  "signal_id": "45049ea8-d1aa-431d-9ac1-9c817cabf3fb",
  "signal_type": "sec-10q",
  "signal_subtype": "goodwillImpairment",
  "detected_at": "2026-11-03T07:12:11.964+00:00",
  "company": {
    "name": "Gilead",
    "domain": "gilead.com"
  },
  "data": {
    "detail": "Gilead recognized an impairment charge of $1.75 billion for the NSCLC IPR&D intangible asset after discontinuing its Phase 3 EVOKE-03 study evaluating Trodelvy. This represents a significant pipeline setback that may prompt management to evaluate external R&D solutions or alternative oncology assets.",
    "metrics": {
      "timeframe": "current_year",
      "dollar_context": "impairment charge of NSCLC IPR&D intangible asset",
      "dollar_millions": 1750
    },
    "quarter": "Q3",
    "summary": "Gilead records $1.75 billion IPR&D impairment following discontinuation of Phase 3 EVOKE-03 study",
    "excerpts": "In consideration of this decision, and in connection with the preparation of the financial statements for the second quarter of 2026, we determined that no future cash flows were expected to be generated in relation to the NSCLC IPR&D intangible asset, and therefore, no value was attributed to the asset. As a result, we recognized an impairment charge of the remaining balance of $1.75 billion in In-process research and development impairments on our Condensed Consolidated Statements of Operations for the nine months ended September 30, 2026.",
    "relevance": 0.8,
    "sentiment": "negative",
    "confidence": "high",
    "source_url": "https://www.sec.gov/Archives/edgar/data/882095/000088209526000039/gild-20260930.htm",
    "filing_date": "2026-10-29",
    "filing_year": 2026,
    "fiscal_year": 2026,
    "fiscal_year_end": "09/30",
    "period_end_date": "2026-09-30",
    "sales_relevance": "Strategic review underway",
    "signal_category": "financial"
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.